Skip Navigation

CAR T-Cell Therapy for Lymphoma

  • CAR T-cell therapy is a promising treatment for some patients with aggressive non-Hodgkin lymphoma (nHL) that has not responded to other therapies (refractory). It is highly-specialized, and involves genetically modifying a patient's T cells to attack their cancer.

    Yescarta (referred to as axicabtagene ciloleucel in the clinical trial phase) was the first CAR T-cell therapy FDA-approved for lymphoma. It is appropriate for some patients with diffuse large B cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, or transformed follicular lymphoma that has relapsed or not responded to prior treatments.

    Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) — the only site in the Northeast to offer Yescarta as part of the clinical trial — was one of the first centers to make this groundbreaking therapy available to more patients.

    Clinical trials of Yescarta showed that 82 percent of patients with treatment-resistant or relapsed aggressive non-Hodgkin lymphoma responded to the CAR T-cell therapy, including 54 percent who had a complete response (i.e., no sign of cancer). The most recent follow-up data shows that at a median 15.4 months after treatment, 40 percent of patients remain in complete remission, showing the lasting effectiveness of this therapy.

    Patients are evaluated carefully to determine if this therapy is appropriate for them.

    DF/BWCC also offers clinical trials evaluating CAR T-cell therapy for other forms of lymphoma.


  • Caron Jacobson, MD, Medical Director of the Immune Effector Cell Therapy program at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), discussed the recent approval of chimeric antigen receptor (CAR) T-cell therapy for certain patients with non-Hodgkin lymphoma in a Facebook Live broadcast.

  • Dana-Farber/ Brigham and Women's Cancer Center
  • Contact Information for CAR T-Cell Therapy

    For more information about CAR T-cell therapy, please call 877-801-CART (2278) or email cartinquiries@dfci.harvard.edu.

  • Pediatric CAR T-Cell Therapy

    Dana-Farber/Boston Children's is a certified treatment center for providing the recently FDA-approved CAR T-cell therapy called KYMRIAH to patients who are up to 25 years old with second or later relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).